Skip to main content
OpenTrials
Completed

NCT Number: NCT03788447

Effect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided Analgesia

The primary purpose of this study is to investigate the effect of pneumoperitoneum on remifentanil requirements in the surgical pleth index-guided analgesia for laparoscopic gastrectomy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine

Suwon, Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • laparoscopic gastrectomy under general anesthesia

Exclusion criteria

  • atypical hemoglobin disease, infective state, cardiovascular disease, peripheral vascular disease

Treatment and study plan

High end-tidal CO2

Other

maintaining of end-tidal CO2 with the range of 40-45 mmHg

Low CO2 group

Other

maintaining of end-tidal CO2 with the range of 30-35 mmHg

Primary outcomes

  1. total dose of remifentanil

    Time frame: through study completion, an average of 2 hours

    total dose of remifentanil to maintain for surgical pleth index < 50

Sponsors and collaborators

Lead sponsor

Ajou University School of Medicine

Other

Registry information

Official study title

Effect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided Analgesia for Laparoscopic Gastrectomy

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 27, 2018
Registry last updated
Jan 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.